Author(s): Lloyd CM, Hessel EM
Abstract Share this page
Abstract Asthma has been considered a T helper 2 (T(H)2) cell-associated inflammatory disease, and T(H)2-type cytokines, such as interleukin-4 (IL-4), IL-5 and IL-13, are thought to drive the disease pathology in patients. Although atopic asthma has a substantial T(H)2 cell component, the disease is notoriously heterogeneous, and recent evidence has suggested that other T cells also contribute to the development of asthma. Here, we discuss the roles of different T cell subsets in the allergic lung, consider how each subset can contribute to the development of allergic pathology and evaluate how we might manipulate these cells for new asthma therapies. TRIAL REGISTRATION: ClinicalTrials.gov NCT00707811 NCT00712205 NCT00968669.
This article was published in Nat Rev Immunol
and referenced in Journal of Clinical & Cellular Immunology